Matrix-assisted cell transplantation for tissue vascularization

Shane Browne; Kevin E Healy

doi:10.1016/j.addr.2018.12.016

Matrix-assisted cell transplantation for tissue vascularization

Adv Drug Deliv Rev. 2019 Jun:146:155-169. doi: 10.1016/j.addr.2018.12.016. Epub 2018 Dec 31.

Authors

Shane Browne¹, Kevin E Healy²

Affiliations

¹ Department of Bioengineering, University of California, Berkeley, CA 94720, USA; Department of Materials Science and Engineering, University of California, Berkeley, CA 94720, USA; Centre for Research in Medical Devices (CÚRAM), National University of Ireland, Galway, Ireland.
² Department of Bioengineering, University of California, Berkeley, CA 94720, USA; Department of Materials Science and Engineering, University of California, Berkeley, CA 94720, USA. Electronic address: kehealy@berkeley.edu.

PMID: 30605738
DOI: 10.1016/j.addr.2018.12.016

Abstract

Cell therapy offers much promise for the treatment of ischemic diseases by augmenting tissue vasculogenesis. Matrix-assisted cell transplantation (MACT) has been proposed as a solution to enhance cell survival and integration with host tissue following transplantation. By designing semi synthetic matrices (sECM) with the correct physical and biochemical signals, encapsulated cells are directed towards a more angiogenic phenotype. In this review, we describe the choice of cells suitable for pro-angiogenic therapies, the properties that should be considered when designing sECM for transplantation and their relative importance. Pre-clinical models where MACT has been successfully applied to promote angiogenesis are reviewed to show the great potential of this strategy to treat ischemic conditions.

Keywords: Angiogenesis; Ischemia; Matrix-assisted Cell Transplantation (MACT); Semi-synthetic matrices (sECM); Vascularization.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Cell Transplantation*
Cell- and Tissue-Based Therapy*
Humans
Mesenchymal Stem Cells*
Neovascularization, Pathologic / therapy*